UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia
Mesenchymal Stem Cell, COVID-19 Pneumonia
About this trial
This is an interventional treatment trial for Mesenchymal Stem Cell focused on measuring umbilical cord mesenchymal stem cells, covid-19 pneumonia, refractory hypoxia
Eligibility Criteria
Inclusion Criteria: The age ranges from 18 to85 (inclusive), regardless of gender. Patients who still have refractory hypoxia after sufficient standard treatment for severe and critical COVID-19 pneumonia following the suggestion of the Chinese diagnostic criteria for COVID-19 pneumonia in the Diagnosis and Treatment Plan for COVID-19 Pneumonia (Tentative tenth Edition). 20kg/m2≤body mass index(BMI)≤30 kg/m2. Volunteer to participate in this clinical study and sign the written informed consent Exclusion Criteria: Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation. T lymphocyte abnormality (allogeneic may be considered, depending on clinical opinion), HIV positive. Highly allergic or have a history of severe allergy, especially Interleukin-2 allergy. Pregnant and lactating women. Patients with severe autoimmune disease history; Allergies to all biological reagents in this treatment, such as Interleukin-2. Patients with serious complications, including chronic cardiac insufficiency (NYHA cardiac function grading assessment of cardiac function grade III - IV), chronic renal insufficiency (CKD stage 3 and above); Chronic liver insufficiency (Child-Pugh score>7); Patients with malignant tumors. Patients with pulmonary embolism or acute coronary syndrome. Patients with severe organ dysfunction caused by other diseases. There are other situations that the researcher thinks are not suitable to participate in this clinical study
Sites / Locations
- Shanghai East Hospital, Shanghai Tongji UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
control
UC-MSCs treatment
Participants will receive standard therapy, including oxygen therapy,glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment on the basis of standard treatment.